Skip to main content
SpringerLink
Log in

The use of metformin in women with polycystic ovary syndrome: an updated review

  • Review
  • Published:
Journal of Assisted Reproduction and Genetics Aims and scope Submit manuscript

Abstract

Purposes

Polycystic ovary syndrome (PCOS) is a major cause of female infertility, being present in up to 20% of women of childbearing age. Insulin resistance (IR) plays an important role in the pathophysiology of PCOS; therefore, its treatment may benefit women with the syndrome. The main drug used for IR management is metformin (MT). We aim to review the literature on the use of metformin in women with PCOS.

Methods

Using the terms “metformin” and “polycystic ovary syndrome,” we conducted a search the PubMed, EMBASE, and Google Scholar databases. The research was restricted to articles published in English. Initially, only published meta-analyses were included, in the absence of meta-analyzes, RCT and well-designed prospective studies were used.

Results

Metformin increases success rates and decreases complication rates when used as an adjunctive medication for ovulation induction during low complexity assisted reproduction treatments and during ovarian stimulation for in vitro fertilization in women with PCOS. Evidence about the effect of metformin on fetal and obstetric complication rates is conflicting. Metformin is associated with high incidence of gastrointestinal symptoms; however, serious adverse effects are rare and there is no evidence of teratogenicity.

Conclusion

For women with PCOS, metformin is a good adjunctive medication for ovulation induction/stimulation for high and low complexity assisted reproduction therapies. The adverse effects are mostly mild, and there is no risk of teratogenicity, but the risk of long-term complications for the offspring is not yet defined. High heterogeneity of the studies limits extrapolation of findings, and further research is needed to determine which women will benefit most from the medication.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bozdag G, et al. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2016;31(12):2841–55.

    Article  Google Scholar 

  2. March WA, et al. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod. 2010;25(2):544–51.

    Article  Google Scholar 

  3. Azziz R. Polycystic Ovary syndrome. Obstet Gynecol. 2018;132(2):321–36.

    Article  Google Scholar 

  4. Yildiz BO, et al. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum Reprod. 2012;27(10):3067–73.

    Article  Google Scholar 

  5. Goldzieher JW, Axelrod LR. Clinical and biochemical features of polycystic ovarian disease. Fertil Steril. 1963;14:631–53.

    Article  CAS  Google Scholar 

  6. Lizneva D, et al. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016;106(1):6–15.

    Article  Google Scholar 

  7. Magoffin DA. Ovarian enzyme activities in women with polycystic ovary syndrome. Fertil Steril. 2006;86(Suppl 1):S9-s11.

    Article  CAS  Google Scholar 

  8. Toulis KA, et al. Adiponectin levels in women with polycystic ovary syndrome: a systematic review and a meta-analysis. Hum Reprod Update. 2009;15(3):297–307.

    Article  CAS  Google Scholar 

  9. Foretz M, et al. Metformin: from mechanisms of action to therapies. Cell Metab. 2014;20(6):953–66.

    Article  CAS  Google Scholar 

  10. Di Pietro M, et al. Metformin has a direct effect on ovarian cells that is dependent on organic cation transporters. Mol Cell Endocrinol. 2019;499:110591.

    Article  Google Scholar 

  11. Sonntag B, et al. Metformin alters insulin signaling and viability of human granulosa cells. Fertil Steril. 2005;84(Suppl 2):1173–9.

    Article  CAS  Google Scholar 

  12. Sharpe A et al. (2019) Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews, (12).

  13. Wang R, et al. First-line ovulation induction for polycystic ovary syndrome: an individual participant data meta-analysis. Hum Reprod Update. 2019;25(6):717–32.

    Article  CAS  Google Scholar 

  14. Misso ML, et al. Metformin versus clomiphene citrate for infertility in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2013;19(1):2–11.

    Article  CAS  Google Scholar 

  15. Abu Hashim H, Foda O, Ghayaty E, Combined metformin-clomiphene in clomiphene-resistant polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Acta Obstet Gynecol Scand, 2015. 94(9): p. 921–30.

  16. Palomba S, Falbo A, La Sala GB. Metformin and gonadotropins for ovulation induction in patients with polycystic ovary syndrome: a systematic review with meta-analysis of randomized controlled trials. Reprod Biol Endocrinol. 2014;12:3.

    Article  Google Scholar 

  17. Kim CH, Chon SJ, Lee SH. Effects of lifestyle modification in polycystic ovary syndrome compared to metformin only or metformin addition: a systematic review and meta-analysis. Sci Rep. 2020;10(1):7802.

    Article  CAS  Google Scholar 

  18. Naderpoor N, et al. Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis. Hum Reprod Update. 2015;21(5):560–74.

    Article  CAS  Google Scholar 

  19. Tso LO et al. (2020) Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database Syst Rev, 12: p. Cd006105.

  20. Wu Y et al. (2020) Association of metformin with pregnancy outcomes in women with polycystic ovarian syndrome undergoing in vitro fertilization: a systematic review and meta-analysis. JAMA Netw Open, 3(8): p. e2011995.

  21. Tan X, et al. Effect of metformin treatment during pregnancy on women with PCOS: a systematic review and meta-analysis. Clin Invest Med. 2016;39(4):E120–31.

    Article  CAS  Google Scholar 

  22. Zeng XL et al. (2016) Effects of metformin on pregnancy outcomes in women with polycystic ovary syndrome: a meta-analysis. Medicine (Baltimore), 95(36): p. e4526.

  23. Zhao J, Liu X, Zhang W. The Effect of metformin therapy for preventing gestational diabetes mellitus in women with polycystic ovary syndrome: a meta-analysis. Exp Clin Endocrinol Diabetes, 2018.

  24. Zhuo Z, Wang A, Yu H. Effect of metformin intervention during pregnancy on the gestational diabetes mellitus in women with polycystic ovary syndrome: a systematic review and meta-analysis. J Diabetes Res, 2014. 2014: p. 381231.

  25. Underdal MO, et al. Does metformin treatment during pregnancy modify the future metabolic profile in women with PCOS? J Clin Endocrinol Metab. 2018;103(6):2408–13.

    Article  Google Scholar 

  26. Patel R, Shah G. Effect of metformin on clinical, metabolic and endocrine outcomes in women with polycystic ovary syndrome: a meta-analysis of randomized controlled trials. Curr Med Res Opin. 2017;33(9):1545–57.

    Article  CAS  Google Scholar 

  27. Wang J et al. Effects of metformin treatment on serum levels of C-reactive protein and interleukin-6 in women with polycystic ovary syndrome: a meta-analysis: a PRISMA-compliant article. Medicine (Baltimore), 2017. 96(39): p. e8183.

  28. Palomba S, et al. Clomiphene citrate, metformin or both as first-step approach in treating anovulatory infertility in patients with polycystic ovary syndrome (PCOS): a systematic review of head-to-head randomized controlled studies and meta-analysis. Clin Endocrinol (Oxf). 2009;70(2):311–21.

    Article  CAS  Google Scholar 

  29. Palomba S, et al. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr Rev. 2009;30(1):1–50.

    Article  CAS  Google Scholar 

  30. Cassina M, et al. First-trimester exposure to metformin and risk of birth defects: a systematic review and meta-analysis. Hum Reprod Update. 2014;20(5):656–69.

    Article  CAS  Google Scholar 

  31. Diav-Citrin O, et al. In-utero exposure to metformin for type 2 diabetes or polycystic ovary syndrome: a prospective comparative observational study. Reprod Toxicol. 2018;80:85–91.

    Article  CAS  Google Scholar 

  32. Scherneck S, et al. Pregnancy outcome after first-trimester exposure to metformin: a prospective cohort study. Reprod Toxicol. 2018;81:79–83.

    Article  CAS  Google Scholar 

  33. Hjorth-Hansen A, et al. Fetal Growth and birth anthropometrics in metformin-exposed offspring born to mothers with PCOS. J Clin Endocrinol Metab. 2018;103(2):740–7.

    Article  Google Scholar 

  34. Hanem LGE, et al. Intrauterine metformin exposure and offspring cardiometabolic risk factors (PedMet study): a 5–10 year follow-up of the PregMet randomised controlled trial. Lancet Child Adolesc Health. 2019;3(3):166–74.

    Article  Google Scholar 

  35. Rowan JA et al. Metformin in gestational diabetes: the offspring follow-up (MiG TOFU): body composition and metabolic outcomes at 7–9 years of age. BMJ Open Diabetes Res Care, 2018. 6(1): p. e000456.

  36. Teede HJ, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018;33(9):1602–18.

    Article  Google Scholar 

  37. Pundir J, et al. Meta-analysis of GnRH antagonist protocols: do they reduce the risk of OHSS in PCOS? Reprod Biomed Online. 2012;24(1):6–22.

    Article  CAS  Google Scholar 

  38. Al-Inany HG et al. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev, 2016. 4: Cd001750.

  39. Jakubowicz DJ, et al. Insulin reduction with metformin increases luteal phase serum glycodelin and insulin-like growth factor-binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome. J Clin Endocrinol Metab. 2001;86(3):1126–33.

    CAS  PubMed  Google Scholar 

  40. Xiong F, et al. Metformin inhibits estradiol and progesterone-induced decidualization of endometrial stromal cells by regulating expression of progesterone receptor, cytokines and matrix metalloproteinases. Biomed Pharmacother. 2019;109:1578–85.

    Article  CAS  Google Scholar 

  41. Dragamestianos C, et al. The Effect of Metformin on the Endometrium of Women with Polycystic Ovary Syndrome. Gynecol Obstet Invest. 2019;84(1):35–44.

    Article  CAS  Google Scholar 

  42. Mao W et al. Efficacy and safety of metformin in the treatment of gestational diabetes: a protocol for systematic review and meta-analysis. Medicine (Baltimore), 2021. 100(1): e23954.

  43. Azziz R, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016;2:16057.

    Article  Google Scholar 

  44. Moran LJ, et al. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2010;16(4):347–63.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Amare Clinic – Brazil, Av. República do Líbano, n 251, torre 1, sala 504, Pina, Recife, PE, CEP 51110-160, Brazil

    Adriana Leal Griz Notaro

  2. Andros Recife Clinic – Brazil, Av. Boa Viagem, n 179, apt 901, Pina, Recife, PE, CEP 51011-000, Brazil

    Filipe Tenorio Lira Neto

Authors
  1. Adriana Leal Griz Notaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Filipe Tenorio Lira Neto
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

AGLN and FTLN conceived and implemented the study. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Filipe Tenorio Lira Neto.

Ethics declarations

Ethics approval

This study was exempted from the institutional review board approval, as it was a review.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Notaro, A.L.G., Neto, F.T.L. The use of metformin in women with polycystic ovary syndrome: an updated review. J Assist Reprod Genet 39, 573–579 (2022). https://doi.org/10.1007/s10815-022-02429-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10815-022-02429-9

Keywords

Search

Navigation